紫杉醇涂层器械对膝下或膝上孤立病变血运重建后保肢与靶血管再干预的影响:SWEDEPAD 1 试验见解
SWEDEPAD 1 预设亚组分析比较紫杉醇涂层与未涂层器械在慢性肢体威胁性缺血(CLTI)股腘或膝下孤立病变中的效果。股腘段1年靶血管再干预(TVR)风险比0.73(95%CI 0.56-0.96),但交互作用不显著且复合终点无获益。
要点
- 紫杉醇涂层器械未改善股腘或膝下孤立病变的保肢率。
- 股腘段1年TVR风险比0.73(95%CI 0.56-0.96),但亚组交互作用不显著。
- 复合终点(同侧截肢或TVR)在股腘段1年无显著获益(HR 0.83,95%CI 0.67-1.04)。
核心结论
- 紫杉醇涂层与未涂层器械在所有腹股沟下节段的保肢率相似。
- 股腘段1年TVR的 apparent 优势未获交互分析支持,且复合终点不稳健。
研究设计与样本
- SWEDEPAD 1 试验的预设亚组分析, pragmatic、多中心、注册-based、随机对照试验。
- 排除同次手术同时处理两节段者,随访至1年、5年及长达10年。
主要发现
- 紫杉醇涂层器械未改善任何节段的保肢率。
- 股腘段1年TVR cause specific HR 0.73(95%CI 0.56-0.96)。
- 膝下段1年TVR cause specific HR 1.04(95%CI 0.67-1.62)。
- 股腘段1年复合终点(同侧截肢或TVR)HR 0.83(95%CI 0.67-1.04)。
临床怎么用
- 在CLTI腹股沟下血运重建中,不应期望紫杉醇涂层器械带来保肢获益。
- 股腘段1年TVR数值降低需谨慎解读,缺乏交互作用支持和复合终点验证。
局限性
- 为预设亚组分析,非主要终点分析,解释需谨慎。
- 排除了同次手术同时处理股腘和膝下节段的患者,可能限制外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the SWEDEPAD 1 trial, paclitaxel coated devices for infrainguinal endovascular revascularisation in chronic limb threatening ischaemia (CLTI) did not improve limb salvage compared with uncoated devices. However, the influence of lesion location on trial outcomes has not been reported previously. The aim of this study was to investigate their impact in isolated femoropopliteal and infrapopliteal lesions. METHODS: This was a pre-specified subgroup analysis of SWEDEPAD 1, a pragmatic, multicentre, registry based, randomised controlled trial comparing paclitaxel coated vs. uncoated devices in infrainguinal revascularisation for CLTI. Patients with Rutherford category 4 - 6 CLTI treated exclusively in the femoropopliteal or infrapopliteal segment were included; those treated in both segments at the same session were excluded. Ipsilateral major amputation and target vessel re-intervention (TVR) rates were assessed at 1, 5, and up to 10 years using Kaplan-Meier estimates and adjusted Cox regression. The trial was pre-registered at ClinicalTrials.gov (NCT02051088). RESULTS: Among 1 778 patients, 1 241 were treated in the femoropopliteal and 537 in the infrapopliteal segment. Paclitaxel coated devices did not improve limb salvage irrespective of vessel segment treated. At 1 year, the TVR cause specific hazard ratio (HR) was 0.73 (95% confidence interval [CI] 0.56 - 0.96) in the femoropopliteal segment and 1.04 (95% CI 0.67 - 1.62) in the infrapopliteal segment. No statistically significant TVR treatment vs. subgroup interactions were observed at 1 year (p = .19), 5 years (p = .41), or during full follow up (p = .51). The composite outcome of ipsilateral limb amputation or TVR did not indicate a benefit at 1 year in the femoropopliteal segment (HR 0.83, 95% CI 0.67 - 1.04). CONCLUSION: Paclitaxel coated and uncoated devices showed similar limb salvage rates across all infrainguinal segments. The apparent one year TVR advantage with paclitaxel coated devices in the femoropopliteal segment was not supported by interaction analysis and was not robust in a net clinical benefit composite endpoint including both TVR and ipsilateral major amputation.
引用
- Le Corvec T, Falkenberg M, Gillgren P, et al. Impact of Paclitaxel Coated Devices on Limb Salvage and Target Vessel Revascularisation Rates following Isolated Femoropopliteal or Infrapopliteal Endovascular Revascularisation for Chronic Limb Threatening Ischaemia: Insights from the SWEDEPAD 1 Trial. Eur J Vasc Endovasc Surg. 2026. PMID: 42456888. doi:10.1016/j.ejvs.2026.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。